|Day Low/High||36.50 / 36.91|
|52 Wk Low/High||28.25 / 37.19|
Pfizer (PFE) will partner with Western Oncolytics to work on its oncolytic virus technology.
We check in on eight companies that already have reported results and three others that will report in the next couple weeks.
Even with half of S&P 500 companies having reported, a clear picture of the earnings season remains murky.
TheStreet highlights 3 stocks pushing the health care sector lower today.
Pfizer Inc. (NYSE:PFE) and Western Oncolytics announced today that they have entered into a development collaboration, license and option agreement to advance Western Oncolytics' novel oncolytic vaccinia virus, WO-12.
A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.
The company sans CEO Scangos needs to do some type of deal in the coming months.
Pfizer shares are up 13% year to date, and the company reports earnings on Aug. 2. Here's what to expect.
Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Pfizer Inc. (NYSE: PFE) announced today that the World Health Organization (WHO) has prequalified its four-dose, multi-dose vial (MDV) presentation of Prevenar 13 ®* (pneumococcal polysaccharide conjugate vaccine [13 -...
We're checking out eight companies in the portfolio that are expected to report results over the next two weeks.
At least one company follower believes the divestiture of Shire's Neurology division for as much as $13 billion would be a logical next move.
TheStreet highlights 3 stocks pushing the health care sector higher today.
The House Republicans' tax reform plan is a pretty good deal according to one analysis, especially for American corporations.
Shares in the U.K.'s leading pharmaceuticals company have risen about 20% since the June 23 Brexit vote.
Corporate governance changes are among the policy flagships unveiled by the successor to David Cameron.
Pfizer Inc. (NYSE:PFE) announced today the publication of findings from two pivotal Phase 3 studies of investigational crisaborole topical ointment 2% (formerly AN2728) in the online issue of the Journal of the American...
The FDA approved Pfizer’s (PFE) pneumonia vaccine for infants and younger adults.
Pfizer Inc. (NYSE:PFE) today announced that Prevnar 13 ® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) received U.
They need to do something that makes them stand out as stocks you want to own, not avoid.
Pfizer Inc. (NYSE:PFE) today announced that the S-TRAC clinical trial ( Sunitinib Trial in Adjuvant Renal Cancer), a Phase 3 study of SUTENT versus placebo in the adjuvant setting, met its primary endpoint of...
Why study charts? Because charts are like the footprints at the scene of the crime, clues to what the big money managers are likely thinking, Cramer says.
A call with investors Wednesday highlights drugs in the pipeline that could be attractive to bidders that reportedly include Sanofi, Pfizer and Celgene, among others.